Explore

Trendline Trendline
Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development

Regeneron and Parabilis Collaborate on $2.3 Billion Antibody-Peptide Conjugate Development
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth
Trendline Trendline
BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth
Trendline Trendline
Novo Nordisk Expands Wegovy Pill Launch Beyond U.S. Amid Global Weight-Loss Market Competition

Novo Nordisk Expands Wegovy Pill Launch Beyond U.S. Amid Global Weight-Loss Market Competition

Novo Nordisk Expands Wegovy Pill Launch Beyond U.S. Amid Global Weight-Loss Market Competition
Trendline Trendline
FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss
Trendline Trendline
Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal
Trendline Trendline
AI in Biotechnology: Transforming Drug Discovery and Personalized Medicine

AI in Biotechnology: Transforming Drug Discovery and Personalized Medicine

AI in Biotechnology: Transforming Drug Discovery and Personalized Medicine
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
Novo Nordisk Expands Wegovy Pill Launch Beyond U.S. Amid Global Obesity Market Competition

Novo Nordisk Expands Wegovy Pill Launch Beyond U.S. Amid Global Obesity Market Competition

Novo Nordisk Expands Wegovy Pill Launch Beyond U.S. Amid Global Obesity Market Competition
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements